Znfpc Spilhaus Center
Harare, Zimbabwe
NCT Number: NCT01956396
The protocol, approved by the Medical Research Council, was issued to assess the safety and efficacy of the non-surgical device for applying it to the national scale up of adult male circumcision in Zimbabwe
Looking for future studies?
Notify Me18 year–30 year
Male
Interventional
Phase 1
Harare, Zimbabwe
Models show that to have the highest impact on the HIV epidemic, circumcision of up to 80% of men in high prevalence countries, where MC rates are low, needs to be achieved (UNAIDS 2009; Manicaland HIV/STD Prevention Project, 2008; Bollinger, et al, 2009). Hallett and colleagues in 2008 showed that for Zimbabwe specifically, HIV incidence could be reduced between 25% to 35% if about 50% of men are circumcised. All modelings conducted show that MC programs must be part of a comprehensive HIV prevention package as MC alone will not tip the HIV epidemic into a terminal decline.
The PrePex Device offers hope for rapid scale up of adult male circumcision in resource limited settings.
Once the safety and efficacy have been established, it is important to conduct operations research to determine how best to implement both device and surgical circumcisions in the national program. Thus, the Zimbabwe MOHCW is planning a three phase trial in order to determine the safety of the PrePexTM device, its performance and the ease of use in an implementation roll out.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
Time frame: 8 week post-procedure follow up appointment and examination
Outcome measures include:
Clinical adverse events and device-related incidents
Time frame: 8 week post-procedure follow up appointment and examination
The total procedure and preparation time of the PrePex™ device circumcision procedure
Time frame: 8 week post-procedure follow up appointment and examination
Pain assessment at key time points using Visual Analog Scale (VAS)
Time frame: 8 week post-procedure follow up appointment and examination
using questionnaires
Time frame: 8 week post-procedure follow up appointment and examination
compliance during use (with follow-up)using questionnaires
Time frame: 8 week post-procedure follow up appointment and examination
procedure acceptability by Doctors using questionnaires
Time frame: 8 week post-procedure follow up appointment and examination
Time frame: 8 week post-procedure follow up appointment and examination
time to complete healing using wound assessment
Time frame: 8 week post-procedure follow up appointment and examination
Time frame: 8 week post-procedure follow up appointment and examination
Procedure acceptability by Nurses using questionnaires
Time frame: 8 week post-procedure follow up appointment and examination
Satisfaction by subjects
Time frame: 8 week post-procedure follow up appointment and examination
using questionnaires
Ministry of Health and Child Welfare, Zimbabwe
Other
Phase I of Study of Safety and Efficacy of the PrePex Device for MC Programs in Zimbabwe
Acronym: ZW-01
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01956383
Circumcision Adult, HIV CDC Category B2
Harare, Zimbabwe
View Trial DetailsNCT01857700
Circumcision Adult, Voluntary Medical Male Circumcision
Kisumu, Nyanza, Kenya
View Trial DetailsNCT06793722
Circumcision, Circumcision Adult
Adıyaman, Turkey (Türkiye)
View Trial DetailsNCT03048422
Blood-Borne Infections, Communicable Diseases
Jacksonville, Florida, United States
View Trial Details